Respiratory infection treating agent

Patent metadata

Field	Value
Publication number	US-10918634-B2
Application number	US-201816189461-A
Country	US
Kind code	B2
Filing date	Nov 13, 2018
Priority date	Mar 13, 2015
Publication date	Feb 16, 2021
Grant date	Feb 16, 2021

Abstract

[Solution] A respiratory infection treating agent containing, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

First claim

The invention claimed is:

1. A method of treating a respiratory infection comprising, administering a compound, wherein the compound is 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in an amount effective to treat the respiratory infection to a subject in need thereof,
wherein the subject is human and
wherein a dose of the compound per day is 75 mg or 150 mg.

2. The method of claim 1 , wherein the respiratory infection is one or more infections selected from the group consisting of pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, and secondary infections of chronic respiratory diseases.

3. The method of claim 1 , wherein pathogenic bacteria causing the respiratory infection are one or more types of bacteria selected from the group consisting of bacteria belonging to Staphylococcus sp., bacteria belonging to Streptococcus sp., Moraxella catarrhalis , bacteria belonging to Klebsiella sp., Haemophilus influenzae , and Escherichia coli.

4. The method of claim 3 , wherein the pathogenic bacteria causing the respiratory infection are bacteria belonging to Streptococcus sp. or Staphylococcus sp.

5. The method of claim 3 , wherein pathogenic bacteria causing the respiratory infection have drug resistance.

6. A method of treating an infection which is one or more infections selected from the group consisting of pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory diseases, sinusitis, and tympanitis, and in which pathogenic bacteria are Streptococcus pneumoniae , the method comprising, administering a compound, wherein the compound is 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in an amount effective to treat the respiratory infection to a subject in need thereof,
wherein the subject is human and
wherein a dose of the compound per day is 75 mg or 150 mg.

7. A method of treating an infection which is one or more infections selected from the group consisting of pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory diseases, sinusitis, and tympanitis, the method comprising administering a compound, wherein the compound is 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, to a subject in need thereof wherein a dose of the compound per day is 75 mg or 150 mg,
wherein the subject is human.

8. The method of claim 1 , wherein a maximum plasma concentration of 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof after administration to the subject is 3 μg/mL or less.

9. The method of claim 1 , wherein a tissue distribution ratio of 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof into an alveolar epithelial lining fluid 1 hour after administration to the subject is 10 or more.

Assignees

• Kyorin Seiyaku Kk

Inventors

• Kume Kota
• Yoshida Hisao
• Ando Hirotaka
• Tanaka Yuta

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P11/04

  for throat disorders · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K31/4709 Primary

  Non-condensed quinolines and containing further heterocyclic rings · CPC title